Core Viewpoint - As of January 30, 2026, the number of common stock shareholders for Zhifei Biological Products Co., Ltd. (stock code: 300122) is reported to be 128,281 [1] Company Summary - Zhifei Biological Products Co., Ltd. has engaged with investors through an interactive platform, providing transparency regarding its shareholder base [1]

Core Viewpoint - Zhifei Biological has received approval from the National Medical Products Administration for clinical trials of its recombinant varicella-zoster virus vaccine (ZFA01) in individuals aged 40 and above, marking a significant advancement in its innovative adjuvant technology platform [1] Group 1: Company Developments - The clinical trial approval for the ZFA01 vaccine is a result of the company's focus on innovation and strengthening core technological capabilities [1] - Successful progress of this project is expected to enrich the company's adult vaccine portfolio and enhance its product layout [1] - The development of this vaccine will further solidify the company's market position in the vaccine industry [1]

Group 1 - The core viewpoint of the article highlights that Zhifei Biological (300122.SZ) has one product under review for market launch and multiple products in clinical trials, indicating ongoing development and potential future offerings [1] - An investor inquiry on the interactive platform noted that major pharmaceutical companies Novo Nordisk and Eli Lilly have significantly exceeded performance expectations, with 85% of their sales coming from the Chinese market, raising questions about Zhifei Biological's ability to regain market share and improve its performance once its products are launched [3]

Group 1 - XianDao Intelligent has set the final price for its H-share public offering at HKD 45.8 per share, with expected listing on February 11, 2026 [1] - Jida Communication is a candidate for a project with China Mobile, with an estimated service fee of approximately CNY 51.04 million [2] - Bowei Alloy's controlling shareholder plans to increase holdings by CNY 100 million to 150 million from February 10 to August 9, 2026 [3] Group 2 - Xiamen Airport reported 16,368 aircraft takeoffs and landings in January 2026, a year-on-year decrease of 4.82%, with passenger throughput of 2.38 million, down 3.84% [4] - Yitong Century has won a bid for a project worth CNY 107 million, providing comprehensive maintenance services for China Tower [5] - Huayi Brothers' controlling shareholder's 70 million shares are subject to judicial auction, representing 42.89% of his holdings and 2.52% of the company's total shares [6] Group 3 - Lianhuan Pharmaceutical received approval for the sale of Tadalafil tablets (20mg) in Ghana [7] - Aonong Biological reported a pig sales volume of 166,600 in January 2026, a year-on-year increase of 35.36% [8] - Xiantan Co. achieved chicken product sales revenue of CNY 546 million in January 2026, a year-on-year increase of 54.9% [9] Group 4 - Zhengbang Technology reported a January sales revenue of CNY 816 million from pig sales, a year-on-year increase of 19.69% [10] - Qianjin Pharmaceutical's net profit for 2025 grew by 24.74% to CNY 288 million [11] - Xinhua Pharmaceutical received a drug registration certificate for glucosamine sulfate capsules [12] Group 5 - Yuandong Bio completed the first dosing of its EP-0210 monoclonal antibody in a Phase I clinical trial for inflammatory bowel disease [13] - Jiaokong Technology signed a contract for the Sydney Metro West Line signal system subcontracting project worth AUD 93.53 million [14] - Dangsheng Technology signed a strategic cooperation framework agreement with Huineng Technology in solid-state batteries and the new energy industry [15] Group 6 - Jinhui Co. plans to acquire 100% of Fusheng Mining for CNY 210 million [16] - Cangzhou Mingzhu announced Guangzhou Light Industry as its new controlling shareholder after a share transfer [17] - Dingxin Technology's vice president was fined CNY 120,000 for short-term trading [18][19] Group 7 - China Modern Pharmaceutical's subsidiary passed a GMP compliance inspection for its production line [20] - Chaosheng Electronics plans to increase capital by CNY 400 million in its subsidiary to enhance competitiveness [21] - Lonyu Mountain reported a 25.03% year-on-year increase in pig sales revenue in January 2026 [22] Group 8 - Sanbo Brain Science's chairman has been released from investigation, and the company is operating normally [23] - Hainan Mining is planning to acquire control of Luoyang Fengrui Fluorine Industry and will resume trading on February 10, 2026 [24] - Dongwei Technology's net profit for 2025 increased by 86.81% [25] Group 9 - Yuanjie Technology plans to invest CNY 1.251 billion in a semiconductor chip and device R&D production base [26] - Metro Design signed a contract for an energy management project with Guangzhou Metro Group worth CNY 924 million [27] - Zhongmin Energy intends to acquire 51% of Fujian Yongtai Mintou Pumped Storage Co. for CNY 864 million [28] Group 10 - Dianzhi Technology plans to repurchase shares worth CNY 100 million to 200 million [29] - China Baoan was not selected as a restructuring investor for the Singshan Group [30] - Zhiguang Electric's subsidiary signed a CNY 1.004 billion contract for energy storage systems [31] Group 11 - Zhifei Biological received approval for a clinical trial of its herpes zoster vaccine [32] - KQ Bio received a new veterinary drug registration certificate for a vaccine against porcine circovirus type 2 [33] - Huanxu Electronics reported a 4% year-on-year increase in consolidated revenue for January 2026 [34] Group 12 - Xiangjia Co. reported a 10.42% year-on-year increase in live poultry sales revenue in January 2026 [35] - Kemin Foods' subsidiary reported a 68.29% year-on-year increase in pig sales revenue in January 2026 [36] - Liyuan Technology signed a procurement contract worth CNY 54.98 million [37] Group 13 - Jiuqiang Bio received a medical device registration certificate for a fibrin degradation product detection kit [38] - Zhongguancun's subsidiary passed the consistency evaluation for Tramadol Hydrochloride tablets [39] - Rundou Co. received a drug registration certificate for Candesartan Etil [40]

Core Viewpoint - The company Zhifei Biological (300122.SZ) has received approval from the National Medical Products Administration for clinical trials of its recombinant herpes zoster vaccine ZFA01 in individuals aged 40 and above, marking a significant advancement in its vaccine development efforts [1] Group 1: Vaccine Development - The recombinant herpes zoster vaccine ZFA01, developed by the company's wholly-owned subsidiary Anhui Zhifei Longkema Biological Pharmaceutical Co., Ltd., has been granted a clinical trial approval notice (Notice No. 2026LP00366) [1] - The vaccine utilizes a novel adjuvant developed in-house, which is expected to stimulate both cellular and humoral immune responses, potentially enhancing the vaccine's protective efficacy [1] Group 2: Market Position and Product Portfolio - As of the announcement date, there are only two approved herpes zoster vaccines available in the domestic market, indicating a competitive opportunity for the company [1] - The approval of the clinical trial application is a result of the company's focus on innovation and strengthening its core technology, which may enrich its adult vaccine offerings and enhance its market position [1]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Anhui Zhifei Longcom Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its recombinant herpes zoster vaccine ZFA01 in individuals aged 40 and above [1] Group 1 - The vaccine ZFA01 is designed to prevent herpes zoster [1] - The clinical trial will focus on a specific demographic, targeting individuals aged 40 years and older [1]

Group 1 - The core point of the article is that Zhifei Biological Products Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of its recombinant varicella-zoster virus vaccine (ZFA01) in individuals aged 40 and above [1] Group 2 - The clinical trial will focus on the prevention of shingles, indicating a strategic move into the vaccine market for older populations [1]

证券代码：300122 证券简称：智飞生物 公告编号：2026-10 获得临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆智飞生物制品股份有限公司（以下简称"公司"）于近日获悉，由全资 子公司安徽智飞龙科马生物制药有限公司（以下简称"智飞龙科马"）研发的重 组带状疱疹 ZFA01 佐剂疫苗（CHO 细胞）获得国家药品监督管理局药物临床试验 批准通知书（通知书编号：2026LP00366），同意在 40 岁及以上人群中开展预防 带状疱疹的临床试验。 一、研发项目简介 重庆智飞生物制品股份有限公司 关于重组带状疱疹 ZFA01 佐剂疫苗（CHO 细胞） 带状疱疹（herpes zoster）是由长期潜伏在脊髓后根神经节或颅神经节内 的水痘-带状疱疹病毒（varicella-zoster virus，VZV）经再激活引起的感染性 皮肤病。有数据表明，90%以上的成人体内都潜伏有水痘-带状疱疹病毒，大约 1/3 的人在一生中会患带状疱疹。带状疱疹是皮肤科常见病，除皮肤损害外，常 伴有神经病理性疼痛，多见于年龄较大、免疫抑制或免疫缺陷等人群 ...

Group 1 - Shanghai Pharmaceuticals plans to transfer 30% equity stake in China and America Bristol-Myers Squibb for no less than 1.023 billion yuan, aiming to optimize investment structure and achieve asset appreciation [1] - The net profit of the target company for the first three quarters of 2025 was 87.11 million yuan, and the transaction is not expected to have a significant impact, although uncertainties exist regarding the buyer [1] Group 2 - Pianzaihuang's controlling shareholder, Jiulongjiang Group, has received a loan commitment from Industrial and Commercial Bank of China for up to 450 million yuan to support the purchase of additional shares [2] - The controlling shareholder plans to use additional self-funding of 300 million to 500 million yuan for the share acquisition, reflecting confidence in the company's value [2] Group 3 - Qizheng Tibetan Medicine's subsidiary has received a registration certificate for the "Cui Tang Granules" from the Macau government, which is a traditional Chinese medicine for respiratory issues [3] - The approval is expected to help expand the company's presence in overseas markets, although it is not anticipated to have a significant impact on recent performance [3] Group 4 - Zhifei Biological's subsidiary has received approval for clinical trials of a freeze-dried varicella inactivated vaccine, which aims to prevent chickenpox and shingles [4] - The vaccine utilizes self-developed technology and fills a gap in the domestic inactivated vaccine market, but is not expected to have a major short-term impact on performance [4] Group 5 - Innovent Biologics forecasts total product revenue of approximately 11.9 billion yuan for 2025, marking a year-on-year growth of about 45% [5] - The company achieved approximately 3.3 billion yuan in total product revenue in the fourth quarter of 2025, with a year-on-year increase of over 60%, driven by steady growth in 13 oncology products and the release of 3 chronic disease medications [5]

Core Insights - Nearly 50% of the 2957 A-share listed companies that disclosed their 2025 annual performance forecasts are expected to incur losses [2][3] - The real estate sector is identified as the most affected, with Vanke A (000002.SZ) being the largest loss-maker, projecting a net loss of approximately 82 billion yuan [6][7] Provincial Distribution of Losses - The provinces with the highest proportion of companies expecting losses are Hainan (44.44%), Jilin (41.67%), and Qinghai (40%) [4][5] - Guangdong has the highest number of companies expecting losses at 257, followed by Beijing (172), Jiangsu (160), and Zhejiang (133) [3][4] Industry Analysis - The IT services and software development sectors have the highest number of companies forecasting losses, with 60 companies each, followed by the real estate sector with 54 companies [6] - The top ten companies with the highest expected losses include five from the real estate sector, with Vanke A leading the list [6][7] Notable Loss-Makers - Vanke A is projected to incur a net loss of about 82 billion yuan due to decreased project settlement scale and increased business risks [6][7] - Other significant loss-makers in the real estate sector include China Fortune Land Development (华夏幸福) with expected losses between 16 billion to 24 billion yuan and Greenland Holdings (绿地控股) with losses of 16 billion to 19 billion yuan [7] - In the retail sector, M.K. Home (美凯龙) is expected to report a loss of 15 billion to 22.5 billion yuan, primarily due to investment property valuation losses [7][8] Sector-Specific Losses - The home appliance sector's largest loss-maker is Shenzhen Konka (深康佳A), projecting losses of 12.58 billion to 15.57 billion yuan [8] - The vaccine leader Zhifei Biological Products (智飞生物) is also expected to report a first-time loss of 10.7 billion to 13.73 billion yuan due to decreased public vaccination willingness [8] - In the photovoltaic sector, Tongwei Co. (通威股份) is projected to incur losses of 9 billion to 10 billion yuan due to industry oversupply and rising raw material costs [9]